Tokyo - Delayed Quote JPY

Nxera Pharma Co., Ltd. (4565.T)

949.00
+2.00
+(0.21%)
At close: 3:30:00 PM GMT+9
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 4565.T

Recent News: 4565.T

View More
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
GlobeNewswire 7 days ago
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
GlobeNewswire 8 days ago
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
GlobeNewswire 12 days ago
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
GlobeNewswire last month
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
GlobeNewswire last month
Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations

Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations
GlobeNewswire last month
Nxera Pharma Announces Appointments to its Executive Leadership Team

Nxera Pharma Announces Appointments to its Executive Leadership Team
GlobeNewswire 2 months ago
Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder

Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
GlobeNewswire 2 months ago
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan
GlobeNewswire 3 months ago
Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera Pharma Assigns Japan and APAC (ex-China) Rights to Cenerimod for Autoimmune Diseases to Viatris
GlobeNewswire 3 months ago
Nxera Pharma Proposes Changes to its Board of Directors

Nxera Pharma Proposes Changes to its Board of Directors
GlobeNewswire 3 months ago
View More

Related Tickers

PRTCl.XC
 
4588.T Oncolys BioPharma Inc.
627.00
-1.88%
 
2160.T GNI Group Ltd.
3,645.00
-7.02%
 
4974.T Takara Bio Inc.
797.00
+1.27%
 
4587.T PeptiDream Inc.
1,696.00
-1.14%
 
MEDCL.PA MedinCell S.A.
16.00
0.00%
 
TRX.L Tissue Regenix Group plc
31.00
-1.59%
 
KLRS Kalaris Therapeutics, Inc.
3.0800
+0.65%
 
DNTH Dianthus Therapeutics, Inc.
18.75
+3.08%
 
FUM.L Futura Medical plc
9.10
-5.21%